Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


23.01.2017

2 Br J Cancer
2 Clin Cancer Res
1 Int J Cancer
4 J Am Acad Dermatol
1 J Invest Dermatol
3 Melanoma Res
4 Oncogene
1 Oncol Rep
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Br J Cancer

  1. DAUD A, Kluger HM, Kurzrock R, Schimmoller F, et al
    Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available

  2. RUSHTON L, Hutchings SJ
    The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation.
    Br J Cancer. 2017 Jan 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  3. DENIGER DC, Kwong ML, Pasetto A, Dudley ME, et al
    A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
    Clin Cancer Res. 2017;23:351-362.
    PubMed     Text format     Abstract available

  4. HAZARIKA M, Chuk MK, Theoret MR, Mushti S, et al
    U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.
    Clin Cancer Res. 2017 Jan 13. pii: clincanres.0712.2016.
    PubMed     Text format     Abstract available


    Int J Cancer

  5. POTRONY M, Rebollo-Morell A, Gimenez-Xavier P, Zimmer L, et al
    IRF4 rs12203592 functional variant and melanoma survival.
    Int J Cancer. 2017 Jan 19. doi: 10.1002/ijc.30605.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  6. VANGIPURAM R, Horner ME, Menter A
    Ethical dilemma in missed melanoma: What to tell the patient and other providers.
    J Am Acad Dermatol. 2017;76:365-367.
    PubMed     Text format    

  7. SOLLENA P, Caldarola G, Di Stefani A, Massi G, et al
    Lichen sclerosus of the glans simulating melanoma.
    J Am Acad Dermatol. 2017;76.
    PubMed     Text format    

  8. PERSECHINO F, Longo C, Benati E, Borsari S, et al
    Acral melanoma.
    J Am Acad Dermatol. 2017;76.
    PubMed     Text format    

  9. GHIGLIOTTI G, De Col E, Rongioletti F
    Parallel globules on the ridges caused by transepidermal elimination of melanocytic nests: A new dermoscopic pattern of acral melanoma.
    J Am Acad Dermatol. 2017;76.
    PubMed     Text format    


    J Invest Dermatol

  10. TSAO H, Fukunaga-Kalabis M, Herlyn M
    Recent Advances in Melanoma and Melanocyte Biology.
    J Invest Dermatol. 2017 Jan 12. pii: S0022-202X(16)32640.
    PubMed     Text format    


    Melanoma Res

  11. LADWA R, Atkinson V
    The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000336.
    PubMed     Text format     Abstract available

  12. TAS F, Erturk K
    Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000332.
    PubMed     Text format     Abstract available

  13. DE HAAN J, Lok CA, de Groot CJ, Crijns MB, et al
    Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000327.
    PubMed     Text format     Abstract available


    Oncogene

  14. BROWN K, Yang P, Salvador D, Kulikauskas R, et al
    WNT/beta-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available

  15. WORRALL C, Suleymanova N, Crudden C, Trocoli Drakensjo I, et al
    Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available

  16. DELYON J, Servy A, Laugier F, Andre J, et al
    PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available

  17. KIM HS, Jung M, Kang HN, Kim H, et al
    Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    Oncol Rep

  18. MADORSKY ROWDO FP, Baron A, von Euw EM, Mordoh J, et al
    In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells.
    Oncol Rep. 2017 Jan 13. doi: 10.3892/or.2017.5363.
    PubMed     Text format     Abstract available


    PLoS One

  19. BINENBAUM Y, Ben-David G, Gil Z, Slutsker YZ, et al
    Cold Atmospheric Plasma, Created at the Tip of an Elongated Flexible Capillary Using Low Electric Current, Can Slow the Progression of Melanoma.
    PLoS One. 2017;12:e0169457.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: